Author: Lucy J. Sannes, PhD, MBA Executive Summary Chapter 1 Introduction Scope of the Report Chapter 2 Review of Selected Major Solid Tumors Targeted by Pharmaceutical Companies 2.1. Brain Cancer 2.2. Breast Cancer 2.3. Cervical Cancer 2.4. Colorectal Cancer 2.5. Head and Neck Cancer 2.6. Lung Canc
|
|
|
Author: Lucy J. Sannes, PhD, MBA TABLES Table 2.1. Incidence and Mortality of Selected Solid Tumors in the United States, 2011 Table 2.2. Five-Year Relative Survival Rates by Stage of Diagnosis (1999–2006) For Selected Major Cancers Targeted by Pharmaceutical Companies Table 3.1. Selected Chemotherapy Drugs
|
Author: Lucy J. Sannes, PhD, MBA Executive Summary Chapter 1 Introduction Scope of the Report Chapter 2 Review of Selected Major Solid Tumors Targeted by Pharmaceutical Companies 2.1. Brain Cancer 2.2. Breast Cancer 2.3. Cervical Cancer 2.4. Colorectal Cancer 2.5. Head and Neck Cancer 2.6. Lung Canc
|
|
|
Author: Lucy J. Sannes, PhD, MBA TABLES Table 2.1. Incidence and Mortality of Selected Solid Tumors in the United States, 2011 Table 2.2. Five-Year Relative Survival Rates by Stage of Diagnosis (1999–2006) For Selected Major Cancers Targeted by Pharmaceutical Companies Table 3.1. Selected Chemotherapy Drugs
|
Author: Lucy J. Sannes, PhD, MBA Executive Summary Chapter 1 Introduction Scope of the Report Chapter 2 Review of Selected Major Solid Tumors Targeted by Pharmaceutical Companies 2.1. Brain Cancer 2.2. Breast Cancer 2.3. Cervical Cancer 2.4. Colorectal Cancer 2.5. Head and Neck Cancer 2.6. Lung Canc
|
Author: Lucy J. Sannes, PhD, MBA
As our understanding of cancer has progressed, newer therapies, such as various targeted therapies and immunotherapy, have become an important part of today's cancer treatment regimens. This report focuses on pharmacological therapies–in particular, the pipelines of
|
Author: Lucy J. Sannes, PhD, MBA TABLES Table 2.1. Incidence and Mortality of Selected Solid Tumors in the United States, 2011 Table 2.2. Five-Year Relative Survival Rates by Stage of Diagnosis (1999–2006) For Selected Major Cancers Targeted by Pharmaceutical Companies Table 3.1. Selected Chemotherapy Drugs
|
Author: Peter Norman, MBA, PhD FIGURES Figure 1.1. NDA and BLA Approvals, 2000–2011 Figure 1.2. The Druggable Genome: a) Exploited, b) Potential Figure 2.1. Schematic Representation of Chemical Space Figure 2.2. Progression to Candidates from Leads Figure 2.3. Progression to Candidates from Fragment Leads Fi
|
Author: K. John Morrow, Jr., PhD
Antibody sales are predicted to reach $50 billion this year. This Insight Pharma Report focuses on recent developments in the therapeutic antibody field and new technologies built on the foundations of previously successful and unsuccessful strategies. Following a review of
|
Author: Peter Norman, MBA, PhD PDF Download Thank you for your interest Click here to download If you have difficulty downloading, please see instructions below. Instructions for downloading the Report Brochure For Windows Users: Right click on the following link, The PI3K/Akt/mTOR Path
|
|
|
Hematological Cancer Therapies Pipelines, Markets, and Business Considerations Authored by Lucy J. Sannes, PhD, MBA | Published February 2012Included in this report 250 pages 16 Tables Over 200 Companies Exclusive content not available in any other research
|
Author: Mark C. Via Executive Summary Chapter 1 BACKGROUND AND SCIENTIFIC OVERVIEW: KINASES ARE IMPORTANT CELLULAR SIGNALING ENZYMES 1.1. The Function of Kinases 1.2. Classifying Kinases TK TKL AGC CAMK CK1 CMGC STE aPK Chapter 2 KINASES AND DISEASE: KINASES ARE A UBIQUITOUS DISEASE TARGET 2.1. The E
|
Executive Summary Chapter 1 INTRODUCTION 1.1. Background 1.2. Scope of the Report Chapter 2 REVIEW OF HEMATOLOGICAL CANCERS (BLOOD CANCERS) 2.1. Leukemia Acute Lymphocytic Leukemia (ALL) Chronic Lymphocytic Leukemia (CLL) Acute Myelogenous (Myeloid) Leukemia (AML) Chronic Myelogenous (Myeloid) Leuke
|
Author: Lucy J. Sannes, PhD, MBA
In recent years, newer and more specific therapies for hematological cancers have been developed, such as targeted small-molecule drugs and biological therapies including monoclonal antibodies. However, there remains significant need from a clinical perspective, as well as
|
Author: Mark C. Via Executive Summary Chapter 1 BACKGROUND AND SCIENTIFIC OVERVIEW: KINASES ARE IMPORTANT CELLULAR SIGNALING ENZYMES 1.1. The Function of Kinases 1.2. Classifying Kinases TK TKL AGC CAMK CK1 CMGC STE aPK Chapter 2 KINASES AND DISEASE: KINASES ARE A UBIQUITOUS DISEASE TARGET 2.1. The E
|
Author Herman AM Mucke, PhD This report provides an analytical snapshot of the current state of the vaccine industry, its development efforts, and an outlook to 2020, examining Vaccines for prevention of infectious diseases including hepatitis, influenza, polio, rabies,
|
Author: Mark C. Via Executive Summary Chapter 1 BACKGROUND AND SCIENTIFIC OVERVIEW: KINASES ARE IMPORTANT CELLULAR SIGNALING ENZYMES 1.1. The Function of Kinases 1.2. Classifying Kinases TK TKL AGC CAMK CK1 CMGC STE aPK Chapter 2 KINASES AND DISEASE: KINASES ARE A UBIQUITOUS DISEASE TARGET 2.1. The E
|